MA56114A - Composés pour le traitement de troubles dépendant de la kinase - Google Patents

Composés pour le traitement de troubles dépendant de la kinase

Info

Publication number
MA56114A
MA56114A MA056114A MA56114A MA56114A MA 56114 A MA56114 A MA 56114A MA 056114 A MA056114 A MA 056114A MA 56114 A MA56114 A MA 56114A MA 56114 A MA56114 A MA 56114A
Authority
MA
Morocco
Prior art keywords
kinase
compounds
treatment
dependent disorders
disorders
Prior art date
Application number
MA056114A
Other languages
English (en)
Inventor
Lynne Canne Bannen
Minna Bui
Faming Jiang
Kin Tso
Yong Wang
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA56114A publication Critical patent/MA56114A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056114A 2019-06-04 2020-06-03 Composés pour le traitement de troubles dépendant de la kinase MA56114A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962856920P 2019-06-04 2019-06-04

Publications (1)

Publication Number Publication Date
MA56114A true MA56114A (fr) 2022-04-13

Family

ID=71842789

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056114A MA56114A (fr) 2019-06-04 2020-06-03 Composés pour le traitement de troubles dépendant de la kinase

Country Status (10)

Country Link
US (1) US12503438B2 (fr)
EP (1) EP3980404A1 (fr)
JP (1) JP7820152B2 (fr)
CN (1) CN114040912B (fr)
AR (1) AR119069A1 (fr)
AU (1) AU2020289324B2 (fr)
CA (1) CA3139156A1 (fr)
MA (1) MA56114A (fr)
TW (1) TWI850394B (fr)
WO (1) WO2020247418A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
CN114573553B (zh) * 2022-01-27 2023-11-10 广州六顺生物科技有限公司 杂芳环类衍生物及其制备方法和应用
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
CN116271008A (zh) * 2022-12-30 2023-06-23 广东天普生化医药股份有限公司 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (fr) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide pour le traitement du cancer
WO2006113546A2 (fr) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
EP2423208A1 (fr) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Composants actifs pharmaceutiquement en tant qu'inhibiteurs Axl
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
JP6696908B2 (ja) * 2014-04-25 2020-05-20 エグゼリクシス, インコーポレイテッド 肺腺癌の治療方法
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
CN110437145A (zh) * 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
SG11202005719UA (en) * 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
WO2019160813A1 (fr) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole en tant qu'agonistes de fxr et leurs procédés d'utilisation

Also Published As

Publication number Publication date
TW202110806A (zh) 2021-03-16
CA3139156A1 (fr) 2020-12-10
AR119069A1 (es) 2021-11-24
US12503438B2 (en) 2025-12-23
AU2020289324B2 (en) 2026-04-23
AU2020289324A1 (en) 2021-12-16
JP2022535108A (ja) 2022-08-04
EP3980404A1 (fr) 2022-04-13
JP7820152B2 (ja) 2026-02-25
TWI850394B (zh) 2024-08-01
CN114040912B (zh) 2024-10-25
US20230043835A1 (en) 2023-02-09
CN114040912A (zh) 2022-02-11
WO2020247418A1 (fr) 2020-12-10

Similar Documents

Publication Publication Date Title
MA51673A (fr) Composés destinés au traitement de troubles dépendant de la kinase
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3935050A4 (fr) Composés hétérocycliques pour traitement médical
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
EP3841086A4 (fr) Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
EP3774743C0 (fr) Composés de type promédicaments activés par akr1c3 et leur utilisation pour le traitement de troubles hyperprolifératifs
EP3941462A4 (fr) Composés pharmaceutiques pour le traitement de troubles médiés par le complément
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
MA51679A (fr) Composés destinés au traitement de troubles dépendant de la kinase
EP3938340A4 (fr) Dérivés aromatiques hétérobicycliques et hétéroaromatiques pour le traitement de troubles liés à la ferroptose
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
MA51738A (fr) Composés pour le traitement de la douleur
EP3805216A4 (fr) Composés pour le traitement ou la prévention de maladies hépatiques
EP3877382A4 (fr) Nouveaux composés pour le traitement de maladies respiratoires
EP3737750A4 (fr) Agents de phosphatase alcaline pour le traitement de troubles neurodéveloppementaux
EP3773644A4 (fr) Protéines pour le traitement de troubles de la fonction de barrière épithéliale
EP3506927A4 (fr) Compositions de reeline pour le traitement des troubles neurologiques
EP4021480A4 (fr) Peptides pour le traitement de troubles rénaux
EP3990458A4 (fr) Composés pour le traitement du cancer
EP3996729C0 (fr) Composition pour la prévention ou le traitement de la dépression ou de l'anxiété
MA56501A (fr) Composés destinés au traitement de troubles neuromusculaires